Revolution Medicines (RVMD) Current Assets (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Current Assets of $2.0 billion for Q1 2026, down 7.81% year-over-year from $2.1 billion in Q1 2025, and down 5.16% quarter-over-quarter from $2.1 billion in Q4 2025.
Revolution Medicines (RVMD) Current Assets (2019 - 2026) Analysis & Trends
Revolution Medicines' Current Assets history runs 8 years deep, the most recent figure standing at $2.0 billion for Q1 2026.
- In Q1 2026, Current Assets fell 7.81% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (down 7.81% YoY), while the FY2025 annual figure was $2.1 billion, down 10.85% from the prior year.
- Current Assets for Q1 2026 stood at $2.0 billion, down from $2.1 billion in the prior quarter.
- The five-year high for Current Assets was $2.3 billion in Q4 2024, with the low at $483.0 million in Q2 2022.
- The 5-year median for Current Assets is $1.6 billion (2024), against an average of $1.4 billion.
- The sharpest annual moves came in 2022 and 2023: Current Assets dropped 26.92% in 2022, then soared 184.66% in 2023.
- Revolution Medicines' Current Assets stood at $660.2 million in 2022, then jumped by 184.66% to $1.9 billion in 2023, then gained by 23.86% to $2.3 billion in 2024, then dropped by 10.85% to $2.1 billion in 2025, then fell by 5.16% to $2.0 billion in 2026.
- Business Quant data shows RVMD's Current Assets at $2.0 billion in Q1 2026, $2.1 billion in Q4 2025, and $2.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.03 Bn |
| Mar 31, 2026 | 1.97 Bn |
| Dec 31, 2025 | 2.08 Bn |
| Sep 30, 2025 | 1.98 Bn |
| Jun 30, 2025 | 2.18 Bn |
| Mar 31, 2025 | 2.13 Bn |
| Dec 31, 2024 | 2.33 Bn |
| Sep 30, 2024 | 1.58 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | 1.73 Bn |
| Dec 31, 2023 | 1.88 Bn |
| Sep 30, 2023 | 824.47 Mn |
| Jun 30, 2023 | 922.09 Mn |
| Mar 31, 2023 | 922.75 Mn |
| Dec 31, 2022 | 660.19 Mn |
| Sep 30, 2022 | 675.11 Mn |
| Jun 30, 2022 | 483.05 Mn |
| Mar 31, 2022 | 534.34 Mn |
| Dec 31, 2021 | 589.77 Mn |
| Sep 30, 2021 | 623.54 Mn |